<DOC>
	<DOCNO>NCT01878396</DOCNO>
	<brief_summary>The purpose study , evaluate Circulating Melanoma Cell ( CMC ) change Metastatic Melanoma ( MM ) patient , undergo treatment selective inhibitor mutate BRAF .</brief_summary>
	<brief_title>Circulating Melanoma Cells Metastatic Patients Treated With Selective BRAF Inhibitors</brief_title>
	<detailed_description>This observational prospective pilot study aim investigate association change total apoptotic CMC count disease progression MM patient undergo treatment selective inhibitor mutate B-RAF .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Fourth stage Melanoma patient measurable measurable lesion undergo treatment selective BRAF inhibitor include . To determine prevalence CMCpositive patient IV stage Melanoma , patient without mutate BRAF undergo chemotherapy and/or vaccine also enrol baseline , part study protocols approve activated participate center . Informed write consent . Inadequate compliance multiple blood draw ( baseline , 15 day , 1th month , 4th month , and/or progression ) schedule adjunctive biologic study patient carry BFAF mutation ; inadequate compliance adjunctive blood draw , schedule baseline BRAF wildtype Previously exposure immunological treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Circulating Melanoma cell metastatic melanoma</keyword>
</DOC>